Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

NCT03998202 · View on ClinicalTrials.gov ↗

Study Summary

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Study Locations (20)

Illinois

  • Illinois CancerCare-Bloomington — Bloomington
  • Illinois CancerCare-Canton — Canton
  • SIH Cancer Institute — Carterville
  • John H Stroger Jr Hospital of Cook County — Chicago
  • Carle at The Riverfront — Danville
  • Cancer Care Specialists of Illinois - Decatur — Decatur
  • Crossroads Cancer Center — Effingham
  • Illinois CancerCare-Galesburg — Galesburg
  • Carle Physician Group - Mattoon/Charleston — Mattoon
  • SSM Health Good Samaritan — Mount Vernon
  • Carle BroMenn Medical Center — Normal
  • Carle Cancer Institute Normal — Normal
  • Cancer Care Center of O'Fallon — O'Fallon

Delaware

  • Beebe South Coastal Health Campus — Millville
  • Helen F Graham Cancer Center — Newark
  • Medical Oncology Hematology Consultants PA — Newark
  • Beebe Health Campus — Rehoboth Beach
  • Christiana Care Health System-Wilmington Hospital — Wilmington

District of Columbia

  • MedStar Georgetown University Hospital — Washington D.C.

Georgia

  • John B Amos Cancer Center — Columbus

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2019-09-23
Est. Completion 2026-12-31

Sponsor

Wake Forest University Health Sciences

1,061 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03998202

The ClinicalTrials.gov registry entry for NCT03998202 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,061 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03998202 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Illinois, Delaware, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03998202 about?

NCT03998202 is a clinical study titled "Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer". This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

What is the current status of trial NCT03998202?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-09-23. Estimated completion is 2026-12-31.

What conditions does trial NCT03998202 study?

This clinical trial studies the following conditions: Colorectal Cancer, Sarcopenia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT03998202?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,061 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03998202 being conducted?

This trial has 20 study locations across Delaware, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial